BALTIMORE, MD--(Marketwire - May 21, 2012) - Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced that it has begun dosing of FP01 lozenges in CLIN01-002-A, an exploratory Phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI). "The data we plan to generate from this and subsequent studies will educate us on the safety and tolerability of FP01, in addition to quantifying the effect size of this novel product for cough," stated Dr. Blake Paterson, CEO of Cerecor. "Advancing FP01 into clinical trials represents a significant milestone both in our Company's history and in the establishment of our clinical pipeline," said Dr. Paterson. "We look forward to rapidly generating the clinical data necessary for the continued development of FP01 lozenges as a potential therapy for chronic and acute cough."
Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. Cerecor's product pipeline also includes preclinical drug development candidates in cognition and schizophrenia. www.cerecor.com